SpineOvations on Feb 24. finished enrollment for its DiscSeal clinical study in patients suffering from lumbar pain.
Three insights:
1. A total of six patients were treated with DiscSeal, a viscous material injected percutaneously into the intervertebral diseased disc of patients under local anesthesia.
2. The product was administered to patients with low back pain caused by discogenic disease and who have not been sufficiently treated by first-line medical therapy.
3. The study aims to evaluate DiscSeal's safety and efficacy in reducing levels of pain from the patients' pre-treatment pain levels over a six-month period.